Research on the Detailed Rules for the Limited Payment Scope of Medical Insurance Drugs Related to Kidney Diseases Based on Delphi method and Consensus Conference Method

doi:10.19546/j.issn.1674-3830.2023.8.019

China Health Insurance ›› 2023, Vol. 0 ›› Issue (8) : 122-126. DOI: 10.19546/j.issn.1674-3830.2023.8.019

Author information +

History +

Abstract

The limited payment scope of some medical insurance drug catalogs is not clearly stated, and there are difficulties in accurate clinical implementation. From the perspective of kidney disease, this paper combs the doubtful items of the limited payment scope of related medical insurance drugs. After three rounds of Delphi method method voting by 30 experts and consensus meeting method voting by 16 experts, seven detailed rules and four revision suggestions are proposed, providing reference for the study of the detailed rules of the limited payment scope of medical insurance drugs, and providing basis for the refined management and clinical precision implementation of the medical insurance department.

Key words

medical insurance drugs / restricted payment / kidney disease / Delphi method / consensus meeting method

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Research on the Detailed Rules for the Limited Payment Scope of Medical Insurance Drugs Related to Kidney Diseases Based on Delphi method and Consensus Conference Method[J]. China Health Insurance. 2023, 0(8): 122-126 https://doi.org/10.19546/j.issn.1674-3830.2023.8.019

References

[1] 靳灵芝.基于德尔菲法和共识会议法的骨质疏松症中医证候研究[D].南京中医药大学,2017.
[2] 葛均波,徐永健,王辰.内科学(第9版)[M].人民卫生出版社,2018.
[3] 中华医学会.临床诊疗指南·肾脏病学分册[M].人民卫生出版社,2012.
[4] 《中成药治疗优势病种临床应用指南》标准化项目组.中成药治疗慢性肾脏病3~5期(非透析)临床应用指南(2020年)[J].中国中西医结合杂志,2021,41(03):261-272.
[5] 王建枝,钱睿哲.病理生理学(第9版)[M].人民卫生出版社,2018.
[6] 贝政平,蔡映云.内科疾病诊断标准(第2版)[M].科学出版社,2007.
[7] 王吉耀,葛均波,邹和建.实用内科学(第16版)[M].人民卫生出版社,2022.
[8] 张智海,刘忠厚,李娜,等.中国人骨质疏松症诊断标准专家共识(第三稿·2014版)[J].中国骨质疏松杂志,2014,20(09):1007-1010.
[9] 最高人民法院.关于审理拐卖妇女儿童犯罪案件具体应用法律若干问题的解释:法释〔2016〕28号[EB/OL].(2016-12-22)[2023-06-30].https://www.court.gov.cn/zixun-xiangqing-33641.html.
[10] 国家药典委员会.中华人民共和国药典临床用药须知化学药和生物制品卷(2020年版)[M].中国医药科技出版社,2022.
[11] 国家药品监督管理局执业药师资格认证中心.药学专业知识(一)(第八版·2023)[M].中国医药科技出版社,2022.
[12] 赵霞,李新民.中医儿科学(第11版)[M].中国中医药出版社,2021.
[13] 温州市人民政府.《儿童权利公约》(儿童版)[EB/OL].https://www.wenzhou.gov.cn/art/2023/6/25/art_1229726127_59210208.html/2023-06-25/2023-06-30.
[14] 《中国国家处方集》编委会.中国国家处方集-化学药品与生物制品卷(2013儿童版)[M].人民军医出版社,2013.
[15] 王卫平,孙锟,常立文.儿科学(第9版)[M].人民卫生出版社,2018.
[16] 万学红,卢雪峰.诊断学(第9版)[M].人民卫生出版社,2018.
[17] 中国吞咽障碍康复评估与治疗专家共识组.中国吞咽障碍评估与治疗专家共识(2017年版)(第一部分评估篇)[J].中华物理医学与康复杂志.2017.39(12):881-892.
[18] 中国慢性肾脏病矿物质和骨异常诊治指南概要[J].肾脏病与透析肾移植杂志,2019,28(01):52-57.
[19] 王丽君.骨化三醇冲击治疗血透患者继发性甲状旁腺功能亢进的研究进展[J].中国处方药,2017,15(08):9-10.
[20] 安徽省成人肾病综合征分级诊疗指南(2016年版)[J].安徽医学,2017,38(05):523-536.
[21] 李世军.肾病综合征患者使用利尿剂的策略[J].肾脏病与透析肾移植杂志,2015,24(06):544-545.
[22] 何雪玲.托拉塞米注射液治疗中老年慢性肾衰竭伴水肿的临床效果分析[J].基层医学论坛,2022,26(01):51-53.
[23] 陈丹丹.局部涂擦多磺酸粘多糖乳膏联合按摩法促进血液透析患者动静脉内瘘成熟效果探究[J].心理月刊,2018(03):200.
[24] 姚鑫儿,任凌燕,王霄一,等.多磺酸粘多糖乳膏在动静脉内瘘皮下出血患者中的应用[J].中国现代医生,2021,59(04):83-86.
[25] 李悦悦.艾灸联合多磺酸粘多糖乳膏防治血液透析动静脉内瘘功能障碍临床研究[J].新中医,2021,53(21):206-209.
[26] 袁心柱,李玲琴,李波良,等.多磺酸黏多糖乳膏联合物理疗法对内瘘功能影响的Meta分析[J].中国中西医结合肾病杂志,2021,22(08):711-714.
[27] 陈香美.血液净化标准规程(2021版)[M].人民卫生出版社,2021.
[28] 孙雪峰.《中国肾性贫血诊疗的临床实践指南》解读[J].中国实用内科杂志,2021,41(09):785-788.
[29] 中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组.肾性贫血诊断与治疗中国专家共识(2018修订版)[J].中华肾脏病杂志,2018,34(11):860-866.
[30] 张连生,邵宗鸿.静脉铁剂应用中国专家共识(2019年版)[J].中华血液学杂志,2019(5):358-362.